Evusheld ‘reduces chances’ of symptomatic COVID-19 by 77%

PROVENT Phase III trial shows at least 6 months protection in high-risk populations

(Photo: Evusheld group)
Detailed results from the PROVENT Phase III pre-exposure prophylaxis (prevention) trial showed that AstraZeneca’s Evusheld (tixagevimab and cilgavimab), formerly AZD7442, reduced the risk of developing symptomatic COVID-19 by 77 percent in the primary analysis and by 83 percent in the six month follow-up analysis, compared to placebo. اضافة اعلان

There were no cases of severe disease or COVID-19-related deaths in the Evusheld group through the six-month follow-up.

More than 75 percent of PROVENT participants at baseline had comorbidities that put them at high risk for severe COVID-19 if they were to become infected, including people who are immunocompromised and may have an inadequate immune response to vaccination.

Additional pharmacokinetic data showed that Evusheld concentrations remained elevated in serum for six months after administration, supporting that a single dose could provide long-term protection against COVID-19 lasting at least six months.

Myron J. Levin, professor of pediatrics and medicine at the University of Colorado School of Medicine, and PROVENT principal investigator on the trial, said: “While COVID-19 vaccines have been highly effective at reducing hospitalization and death, cases continue to surge and many individuals remain at high risk, including immunocompromised individuals and those who cannot be vaccinated. These important data now published in the New England Journal of Medicine provide confidence that one easily administered intramuscular dose of Evusheld couldprovide vulnerable populations long-lasting protection. In addition, Evusheld has been shown to neutralize BA.2, currently the dominant circulating COVID-19 variant.”

Mene Pangalos, executive vice president, BioPharmaceuticals R&D, AstraZeneca, said:   "These data add to the growing body of evidence supporting the use of Evusheld to help prevent symptomatic and severe COVID-19, especially for those individuals who can’t respond adequately to vaccination and need additional protection. Evusheld is now available in many countries around the world, and we are progressing filings in pre-exposure prophylaxis as well as mild-to-moderate treatment.”

The data were published online in the New England Journal of Medicine.  

Read more Business
Jordan News